198 related articles for article (PubMed ID: 29765517)
1. Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma.
Ogura S; Yoshida Y; Kurahashi T; Egawa M; Furuta K; Kiso S; Kamada Y; Hikita H; Eguchi H; Ogita H; Doki Y; Mori M; Tatsumi T; Takehara T
Oncotarget; 2018 Apr; 9(30):21022-21035. PubMed ID: 29765517
[TBL] [Abstract][Full Text] [Related]
2. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma.
Xia L; Huang W; Tian D; Zhu H; Zhang Y; Hu H; Fan D; Nie Y; Wu K
J Hepatol; 2012 Sep; 57(3):600-12. PubMed ID: 22613004
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death.
Pandyra AA; Mullen PJ; Goard CA; Ericson E; Sharma P; Kalkat M; Yu R; Pong JT; Brown KR; Hart T; Gebbia M; Lang KS; Giaever G; Nislow C; Moffat J; Penn LZ
Oncotarget; 2015 Sep; 6(29):26909-21. PubMed ID: 26353928
[TBL] [Abstract][Full Text] [Related]
4. Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with Ras/Forkhead box M1 signaling pathway.
Park YH; Kim SU; Kwon TH; Kim JM; Song IS; Shin HJ; Lee BK; Bang DH; Lee SJ; Lee DS; Chang KT; Kim BY; Yu DY
Oncogene; 2016 Jul; 35(27):3503-13. PubMed ID: 26500057
[TBL] [Abstract][Full Text] [Related]
5. Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy.
Xue L; Qi H; Zhang H; Ding L; Huang Q; Zhao D; Wu BJ; Li X
Front Oncol; 2020; 10():1510. PubMed ID: 32974183
[TBL] [Abstract][Full Text] [Related]
6. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
7. The TNF-α/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis.
Xia L; Mo P; Huang W; Zhang L; Wang Y; Zhu H; Tian D; Liu J; Chen Z; Zhang Y; Chen Z; Hu H; Fan D; Nie Y; Wu K
Carcinogenesis; 2012 Nov; 33(11):2250-9. PubMed ID: 22831955
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of Forkhead box M1 transcription factor is associated with clinicopathological features and confers a poor prognosis in human hepatocellular carcinoma.
Egawa M; Yoshida Y; Ogura S; Kurahashi T; Kizu T; Furuta K; Kamada Y; Chatani N; Hamano M; Kiso S; Hikita H; Tatsumi T; Eguchi H; Nagano H; Doki Y; Mori M; Takehara T
Hepatol Res; 2017 Oct; 47(11):1196-1205. PubMed ID: 28002884
[TBL] [Abstract][Full Text] [Related]
9. Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC.
Calvisi DF; Pinna F; Ladu S; Pellegrino R; Simile MM; Frau M; De Miglio MR; Tomasi ML; Sanna V; Muroni MR; Feo F; Pascale RM
Gut; 2009 May; 58(5):679-87. PubMed ID: 19136513
[TBL] [Abstract][Full Text] [Related]
10. LXRα-mediated downregulation of FOXM1 suppresses the proliferation of hepatocellular carcinoma cells.
Hu C; Liu D; Zhang Y; Lou G; Huang G; Chen B; Shen X; Gao M; Gong W; Zhou P; Dai S; Zeng Y; He F
Oncogene; 2014 May; 33(22):2888-97. PubMed ID: 23812424
[TBL] [Abstract][Full Text] [Related]
11. Elevated expression of FoxM1 promotes the tumor cell proliferation in hepatocellular carcinoma.
Yu M; Tang Z; Meng F; Tai M; Zhang J; Wang R; Liu C; Wu Q
Tumour Biol; 2016 Jan; 37(1):1289-97. PubMed ID: 26289845
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma.
Sun HC; Li M; Lu JL; Yan DW; Zhou CZ; Fan JW; Qin XB; Tang HM; Peng ZH
Oncol Rep; 2011 Jun; 25(6):1533-9. PubMed ID: 21431285
[TBL] [Abstract][Full Text] [Related]
13. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.
Mo H; Jeter R; Bachmann A; Yount ST; Shen CL; Yeganehjoo H
Front Pharmacol; 2018; 9():1515. PubMed ID: 30662405
[TBL] [Abstract][Full Text] [Related]
14. Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma.
Tran GB; Ding J; Ye B; Liu M; Yu Y; Zha Y; Dong Z; Liu K; Sudarshan S; Ding HF
Cancer Res; 2023 Jul; 83(13):2248-2261. PubMed ID: 37057874
[TBL] [Abstract][Full Text] [Related]
15. Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features.
Kopanja D; Pandey A; Kiefer M; Wang Z; Chandan N; Carr JR; Franks R; Yu DY; Guzman G; Maker A; Raychaudhuri P
J Hepatol; 2015 Aug; 63(2):429-36. PubMed ID: 25828473
[TBL] [Abstract][Full Text] [Related]
16. Nuclear accumulation of glioma-associated oncogene 2 protein and enhanced expression of forkhead-box transcription factor M1 protein in human hepatocellular carcinoma.
Lin M; Guo LM; Liu H; Du J; Yang J; Zhang LJ; Zhang B
Histol Histopathol; 2010 Oct; 25(10):1269-75. PubMed ID: 20712011
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 regulates glycolysis in hepatocellular carcinoma by transactivating glucose transporter 1 expression.
Shang R; Pu M; Li Y; Wang D
Oncol Rep; 2017 Apr; 37(4):2261-2269. PubMed ID: 28260073
[TBL] [Abstract][Full Text] [Related]
18. ACP5, a direct transcriptional target of FoxM1, promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma.
Xia L; Huang W; Tian D; Chen Z; Zhang L; Li Y; Hu H; Liu J; Chen Z; Tang G; Dou J; Sha S; Xu B; Liu C; Ma J; Zhang S; Li M; Fan D; Nie Y; Wu K
Oncogene; 2014 Mar; 33(11):1395-406. PubMed ID: 23604121
[TBL] [Abstract][Full Text] [Related]
19. Gypenoside L inhibits hepatocellular carcinoma by targeting the SREBP2-HMGCS1 axis and enhancing immune response.
Xiao MY; Pei WJ; Li S; Li FF; Xie P; Luo HT; Hyun Yoo H; Piao XL
Bioorg Chem; 2024 Jun; 150():107539. PubMed ID: 38861912
[TBL] [Abstract][Full Text] [Related]
20. Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma.
Fan W; Ma H; Jin B
Oncol Lett; 2022 May; 23(5):146. PubMed ID: 35350587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
